Sitagliptin 50 mg Tablets (Sitagliptin Phosphate)
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Alkico Pharmaceuticals Co., Ltd.
MFDS item code 201507869 · Approved 2015.11.25
This product's status changed to Expired on 2025.11.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. It can also be administered as monotherapy, and in cases where prior diabetes medication treatment has not been effective in achieving adequate blood sugar control, it is administered in conjunction with metformin. Additionally, it may be used alongside sulfonylureas, metformin, thiazolidinediones, or insulin when blood sugar control is insufficient with monotherapy to enhance effectiveness. This medication helps manage blood sugar at various stages of treatment.
This drug is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, evaluation of renal function is recommended before and periodically after starting treatment with this drug. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.
This medication may rarely cause serious allergic reactions. Possible reactions include severe skin rashes or swelling and shortness of breath; if these symptoms occur, use should be stopped immediately and advice sought from a doctor. Additionally, this medication can cause pancreatitis, an inflammation of the pancreas. Symptoms of pancreatitis include abdominal pain, vomiting, and nausea; if these symptoms occur, medication should be stopped immediately and medical attention sought. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and is also contraindicated in patients with a known allergy to this medication or its components. Patients with impaired kidney function may not adequately excrete the medication from the body, requiring dosage adjustments or careful use, as regular kidney function tests are recommended. Adverse effects reported from clinical trials and post-marketing surveillance include upper respiratory infections, headaches, nasopharyngitis, diarrhea, and particularly, there may be an increased risk of hypoglycemia when used with insulin or sulfonylureas, necessitating careful blood sugar monitoring. Furthermore, if during the use of this medication there is severe joint pain, muscle pain, skin blisters, or rashes, it is critical to inform a doctor and potentially discontinue use. The safety of this medication has not been established in pregnant or breastfeeding women; therefore, it is recommended to avoid use in those situations. In cases of overdose, gastrointestinal decontamination should be conducted, and monitoring of cardiovascular status, such as ECG, should occur; some medication may be removed via hemodialysis if necessary. Lastly, this medication can increase the risk of hypoglycemia when used in combination with other hypoglycemic agents, making it important to consult with a doctor or pharmacist about interactions with other medications being taken.
Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative skin conditions, acute pancreatitis, hypoglycemia, upper respiratory tract infections, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia accompanied by severe and disability, vesicular dermatitis resembling pemphigus, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzyme levels, acute kidney failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, elevated low-density lipoprotein, hyperglycemia
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air exposure, ideally at a temperature between 1°C to 30°C. Proper storage will help maintain its effectiveness.
Light beige, round, biconvex film-coated tablet
28 tablets (14 tablets/PTP × 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Alkico Pharmaceuticals Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.